Association of early dexmedetomidine exposure with brain injury biomarker levels following moderate – Severe traumatic brain injury: A TRACK-TBI study
Wongsripuemtet P, Ohnuma T, Temkin N, Barber J, Komisarow J, Manley G, Hatfield J, Treggiari M, Colton K, Sasannejad C, Chaikittisilpa N, Ivins-O’Keefe K, Grandhi R, Laskowitz D, Mathew J, Hernandez A, James M, Raghunathan K, Miller J, Vavilala M, Krishnamoorthy V, investigators T. Association of early dexmedetomidine exposure with brain injury biomarker levels following moderate – Severe traumatic brain injury: A TRACK-TBI study. Journal Of Clinical Neuroscience 2024, 126: 338-347. PMID: 39029302, DOI: 10.1016/j.jocn.2024.07.003.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-2 Receptor AgonistsAdultBiomarkersBrain Injuries, TraumaticCohort StudiesDexmedetomidineFemaleGlasgow Coma ScaleHumansHypnotics and SedativesMaleMiddle AgedRetrospective StudiesConceptsC-reactive proteinNeuron-specific enolaseGlial fibrillary acidic proteinBiomarker levelsUbiquitin C-terminal hydrolase-L1Traumatic brain injuryDexmedetomidine exposureInjury biomarkersSevere traumatic brain injuryTRACK-TBIS100 calcium-binding protein BInflammatory biomarkers C-reactive proteinCalcium-binding protein BHs-CRP levelsLevel 1 trauma centerRetrospective cohort studyCritically ill TBI patientsAlpha-2 agonistsBrain injuryBrain injury biomarkersBiomarkers C-reactive proteinModulate autonomic functionGlasgow Coma Scale score 3No significant associationSecondary brain injury